Curcumin / BioAv Cancer Research Results

CUR, Curcumin: Click to Expand ⟱
Features:
Curcumin is the main active ingredient in Tumeric. Member of the ginger family.Curcumin is a polyphenol extracted from turmeric with anti-inflammatory and antioxidant properties.
- Has iron-chelating, iron-chelating properties. Ferritin. But still known to increase Iron in Cancer cells.
- GSH depletion in cancer cells, exhaustion of the antioxidant defense system. But still raises GSH↑ in normal cells.
- Higher concentrations (5-10 μM) of curcumin induce autophagy and ROS production
- Inhibition of TrxR, shifting the enzyme from an antioxidant to a prooxidant
- Strong inhibitor of Glo-I, , causes depletion of cellular ATP and GSH
- Curcumin has been found to act as an activator of Nrf2, (maybe bad in cancer cells?), hence could be combined with Nrf2 knockdown
-may suppress CSC: suppresses self-renewal and pathways (Wnt/Notch/Hedgehog).
Clinical studies testing curcumin in cancer patients have used a range of dosages, often between 500 mg and 8 g per day; however, many studies note that doses on the lower end may not achieve sufficient plasma concentrations for a therapeutic anticancer effect in humans.
• Formulations designed to improve curcumin absorption (like curcumin combined with piperine, nanoparticle formulations, or liposomal curcumin) are often employed in clinical trials to enhance its bioavailability.

-Note half-life 6 hrs.
BioAv is poor, use piperine or other enhancers
Pathways:
- induce ROS production at high concentration. Lowers ROS at lower concentrations
curcumin can act as a pro-oxidant when blue light is applied
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓
- Lowers AntiOxidant defense in Cancer Cells: GSH↓ Catalase↓ HO1↓ GPx↓
but conversely is known as a NRF2↑ activator in cancer
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, uPA↓, VEGF↓, NF-κB↓, CXCR4↓, SDF1↓, TGF-β↓, α-SMA↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMT1↓, DNMT3A↓, EZH2↓, P53↑, HSP↓, Sp proteins↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, ERK↓, EMT↓, TOP1↓, TET1↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDHA↓, HK2↓, PFKs↓, PDKs↓, HK2↓, ECAR↓, OXPHOS↓, GRP78↑, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- inhibits Cancer Stem Cells : CSC↓, CK2↓, Hh↓, GLi1↓, CD133↓, CD24↓, β-catenin↓, n-myc↓, sox2↓, OCT4↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK↓, ERK↓, JNK, TrxR**,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Rank Pathway / Axis Cancer Cells Normal Cells Label Primary Interpretation Notes
1 NF-κB signaling ↓ NF-κB activation ↓ inflammatory NF-κB tone Driver Suppression of survival and inflammatory transcription NF-κB is a primary, repeatedly validated curcumin target explaining pleiotropic downstream effects
2 STAT3 signaling ↓ STAT3 phosphorylation / activity ↔ or mild suppression Driver Loss of pro-survival and proliferative signaling STAT3 inhibition contributes to growth arrest, apoptosis sensitization, and reduced cytokine signaling in tumors
3 Reactive oxygen species (ROS) ↑ ROS (dose- & context-dependent) ↓ ROS / buffered Conditional Driver Biphasic redox modulation Curcumin can act as a pro-oxidant in cancer cells with high basal stress while acting antioxidant in normal cells
4 Mitochondrial integrity / intrinsic apoptosis ↓ ΔΨm; ↑ caspase activation ↔ preserved Driver Execution of intrinsic apoptosis Mitochondrial dysfunction and caspase activation occur downstream of NF-κB/STAT3 and ROS effects
5 PI3K → AKT → mTOR axis ↓ AKT / ↓ mTOR ↔ or adaptive suppression Secondary Reduced growth and anabolic signaling AKT/mTOR inhibition contributes to growth suppression and autophagy induction in cancer cells
6 Autophagy ↑ autophagy (protective or pro-death) ↑ adaptive autophagy Secondary Stress adaptation vs cell death Autophagy may be cytoprotective or cooperate with apoptosis depending on context and dose
7 HIF-1α / VEGF hypoxia–angiogenesis axis ↓ HIF-1α; ↓ VEGF ↔ minimal effect Secondary Anti-angiogenic pressure Suppression of hypoxia-driven transcription limits angiogenesis and tumor adaptation
8 Cell cycle regulation ↑ G2/M or G1 arrest ↔ largely spared Phenotypic Cytostatic growth control Cell-cycle arrest reflects upstream signaling and epigenetic effects rather than direct CDK inhibition
9 Migration / invasion (EMT, MMP axis) ↓ migration & invasion ↔ Phenotypic Anti-metastatic phenotype Reduced EMT markers and protease activity limit invasive behavior
10 Epigenetic regulation (p300/CBP HAT activity) ↓ histone acetylation ↔ modest Secondary Transcriptional reprogramming Curcumin modulates chromatin via HAT inhibition rather than classic HDAC inhibition


BioAv, bioavailability: Click to Expand ⟱
Source:
Type: measurement
Bioavailability (usually in %) absorbed by the body.
Scientific Papers found: Click to Expand⟱
2015- CAP,  CUR,  urea,    Anti-cancer Activity of Sustained Release Capsaicin Formulations
- Review, Var, NA
AntiCan↑, TumCG↓, angioG↓, TumMeta↓, BioAv↓, BioAv↓, BioAv↑, selectivity↑, EPR↑, eff↓, ChemoSen↑, Dose∅, Half-Life∅, eff↑,
4651- CUR,    Targeting cancer stem cells by curcumin and clinical applications
- Review, Var, NA
CSCs↓, *toxicity↓, *BioAv↝, chemoP↑,
4655- CUR,    Inhibition of Cancer Stem-like Cells by Curcumin and Other Polyphenol Derivatives in MDA-MB-231 TNBC Cells
- in-vitro, BC, NA
CSCs↓, *BioAv↓,
4829- CUR,    Dual Action of Curcumin as an Anti- and Pro-Oxidant from a Biophysical Perspective
- Review, Var, NA
*antiOx↑, ROS↑, *lipid-P↓, *iNOS↓, *BioAv↓,
4826- CUR,    The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management
- Review, Var, NA
*antiOx↑, *Inflam↑, *ROS↓, Apoptosis↑, TumCP↓, BioAv↓, Half-Life↓, eff↑, TumCCA↑, BAX↑, Bak↑, PUMA↑, BIM↑, NOXA↑, TRAIL↑, Bcl-2↓, Bcl-xL↓, survivin↓, XIAP↓, cMyc↓, Casp↑, NF-kB↓, STAT3↓, AP-1↓, angioG↓, TumMeta↑, VEGF↓, MMPs↓, DNMTs↓, HDAC↓, ROS↑,
4672- CUR,    An old spice with new tricks: Curcumin targets adenoma and colorectal cancer stem-like cells associated with poor survival outcomes
- vitro+vivo, CRC, HCT116
CSCs↓, Nanog↓, BioAv↓,
2817- CUR,    Neuroprotection by curcumin: A review on brain delivery strategies
- Review, Nor, NA
*BioAv↝, neuroP↑,
2816- CUR,    NEUROPROTECTIVE EFFECTS OF CURCUMIN
- Review, AD, NA - Review, Park, NA
*neuroP↑, *Inflam↓, *antiOx↑, *BioAv↓, *AP-1↓, *NF-kB↓, *HATs↓, *HDAC↑, Dose↑, *ROS↓, *cognitive↑, *Aβ↓,
2814- CUR,    Curcumin in Cancer and Inflammation: An In-Depth Exploration of Molecular Interactions, Therapeutic Potentials, and the Role in Disease Management
- Review, Var, NA
*BioAv↓, *Inflam↓, *antiOx↑, AntiCan↑, CK2↓, GSK‐3β↓, EGFR↓, TOP1↓, TOP2↓, NF-kB↓, COX2↓, CRP↓,
2308- CUR,    Counteracting Action of Curcumin on High Glucose-Induced Chemoresistance in Hepatic Carcinoma Cells
- in-vitro, Liver, HepG2
GlucoseCon↓, lactateProd↓, ECAR↓, NO↓, ROS↑, HK2↓, PFK1↓, GAPDH↓, PKM2↓, LDHA↓, FASN↓, GLUT1↓, MCT1↓, MCT4↓, HCAR1↓, SDH↑, ChemoSen↑, ROS↑, BioAv↑, P53↑, NF-kB↓, pH↑,
2809- CUR,    Comparative absorption of curcumin formulations
- in-vivo, Nor, NA
BioAv↑, BioAv↑, BioAv↑, BioAv↑, BioAv↑, BioAv↓, Half-Life↝,
2688- CUR,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, Var, NA - Review, AD, NA
*ROS↓, *SOD↑, p16↑, JAK2↓, STAT3↓, CXCL12↓, IL6↓, MMP2↓, MMP9↓, TGF-β↓, α-SMA↓, LAMs↓, DNAdam↑, *memory↑, *cognitive↑, *Inflam↓, *antiOx↑, *NO↑, *MDA↓, *ROS↓, DNMT1↓, ROS↑, Casp3↑, Apoptosis↑, miR-21↓, LC3II↓, ChemoSen↑, NF-kB↓, CSCs↓, Nanog↓, OCT4↓, SOX2↓, eff↑, Sp1/3/4↓, miR-27a-3p↓, ZBTB10↑, SOX9?, ChemoSen↑, VEGF↓, XIAP↓, Bcl-2↓, cycD1/CCND1↓, BioAv↑, Hif1a↓, EMT↓, BioAv↓, PTEN↑, VEGF↓, Akt↑, EZH2↓, NOTCH1↓, TP53↑, NQO1↑, HO-1↑,
2654- CUR,    Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence
- Review, Var, NA
ROS↑, Catalase↓, SOD1↓, GLO-I↓, NADPH↓, TumCCA↑, Apoptosis↑, Akt↓, ER Stress↑, JNK↑, STAT3↓, BioAv↑,
3579- CUR,  AgNPs,    Metal–Curcumin Complexes in Therapeutics: An Approach to Enhance Pharmacological Effects of Curcumin
- Review, NA, NA
*IronCh↑, *BioAv↑, *antiOx↑, *Inflam↓, *BioAv↑, ROS↑, *neuroP↑, *eff↑,
3590- CUR,    The Holy Grail of Curcumin and its Efficacy in Various Diseases: Is Bioavailability Truly a Big Concern?
- Review, Var, NA - Review, AD, NA
*BioAv↓, *BioAv↑, Dose↑, *Dose↝, *BBB↑, *cognitive↑, *BioAv↑,
2305- CUR,    Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN
- in-vitro, BC, MCF-7
BioAv↑, PKM2↓, FASN↓, Glycolysis↓,
3588- CUR,    The effect of curcumin on cognition in Alzheimer’s disease and healthy aging: A systematic review of pre-clinical and clinical studies
- Review, AD, NA
*cognitive↝, *BioAv↑, *Inflam↓, *COX2↓, *iNOS↓, *NF-kB↓, *TNF-α↓, *IL1↓, *IL2↓, *IL6↓, *IL8↓, *IL12↓, *ROS↓, *RNS↓, *antiOx↑, *BBB↑, *BioAv↓, *cognitive↑, *memory↑, *tau↓, *eff↑,
3586- CUR,  PI,    Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers
- in-vivo, NA, NA
*BioAv↑,
3585- CUR,    Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer
- Study, NA, NA
*BioAv↑,
3582- CUR,  PI,    Therapeutic and Preventive Effects of Piperine and its Combination with Curcumin as a Bioenhancer Against Aluminum-Induced Damage in the Astrocyte Cells
*eff↑, *IL6↓, *TGF-β↓, *BioAv↑,
3578- CUR,  SIL,    Curcumin, but not its degradation products, in combination with silibinin is primarily responsible for the inhibition of colon cancer cell proliferation
- in-vitro, CRC, DLD1
eff↑, BioAv↓, TumCG↓,
3577- CUR,    Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study
- Trial, AD, NA
*cognitive∅, *BioAv↑,
3576- CUR,    Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer's Disease
- Review, AD, NA
*Inflam↓, *antiOx↑, *memory↑, *Aβ↓, *BBB↑, *cognitive↑, *tau↓, *LDL↓, *AChE↓, *IL1β↓, *IronCh↑, *neuroP↑, *BioAv↝, *PI3K↑, *Akt↑, *NRF2↑, *HO-1↑, *Ferritin↑, *HO-2↓, *ROS↓, *Ach↑, *GSH↑, *Bcl-2↑, *ChAT↑,
3574- CUR,    The effect of curcumin (turmeric) on Alzheimer's disease: An overview
- Review, AD, NA
*antiOx↑, *Inflam↓, *lipid-P↓, *cognitive↑, *memory↑, *Aβ↓, *COX2↓, *ROS↓, *AP-1↓, *NF-kB↓, *TNF-α↓, *IL1β↓, *SOD↑, *GSH↑, *HO-1↑, *IronCh↑, *BioAv↓, *Half-Life↝, *Dose↝, *BBB↑, *BioAv↑, *toxicity∅, *eff↑,
146- CUR,  EGCG,    Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, DU145
P21↑, TumCCA↑, TumCP↓, BioAv↓,
125- CUR,    Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway
- in-vitro, adrenal, H295R
CYP17A1↓, CYP19↓, *Nrf1↑, *NF-kB↓, angioG↓, Apoptosis↑, AR↓, toxicity↓, BioAv↑,
4904- Sal,  CUR,    Co-delivery of Salinomycin and Curcumin for Cancer Stem Cell Treatment by Inhibition of Cell Proliferation, Cell Cycle Arrest, and Epithelial–Mesenchymal Transition
CSCs↓, TumCCA↑, EMT↓, other↝, TumAuto↑, Iron↑, Ferroptosis↑, BioAv↓, ROS↑, lipid-P↑, GPx4↓, eff↑,
4752- SeNPs,  CUR,  Chemo,    Curcumin-Modified Selenium Nanoparticles Improve S180 Tumour Therapy in Mice by Regulating the Gut Microbiota and Chemotherapy
- in-vitro, Cerv, HeLa - in-vitro, sarcoma, S180
tumCV↓, ROS↑, *GutMicro↑, BioAv↑, other↝, Dose↝,
139- Tomatine,  CUR,    Combination of α-Tomatine and Curcumin Inhibits Growth and Induces Apoptosis in Human Prostate Cancer Cells
- in-vitro, Pca, PC3
NF-kB↓, Bcl-2↓, p‑Akt↓, p‑ERK↓, TumCG↓, Apoptosis↑, PCNA↓, BioAv↓,

Showing Research Papers: 1 to 29 of 29

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 29

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↓, 1,   Ferroptosis↑, 1,   GPx4↓, 1,   HO-1↑, 1,   Iron↑, 1,   lipid-P↑, 1,   NQO1↑, 1,   ROS↑, 9,   SOD1↓, 1,  

Mitochondria & Bioenergetics ⓘ

SDH↑, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,   ECAR↓, 1,   FASN↓, 2,   GAPDH↓, 1,   GLO-I↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 1,   HK2↓, 1,   lactateProd↓, 1,   LDHA↓, 1,   MCT4↓, 1,   NADPH↓, 1,   PFK1↓, 1,   PKM2↓, 2,  

Cell Death ⓘ

Akt↓, 1,   Akt↑, 1,   p‑Akt↓, 1,   Apoptosis↑, 5,   Bak↑, 1,   BAX↑, 1,   Bcl-2↓, 3,   Bcl-xL↓, 1,   BIM↑, 1,   Casp↑, 1,   Casp3↑, 1,   CK2↓, 1,   Ferroptosis↑, 1,   JNK↑, 1,   MCT1↓, 1,   NOXA↑, 1,   PUMA↑, 1,   survivin↓, 1,   TRAIL↑, 1,  

Kinase & Signal Transduction ⓘ

SOX9?, 1,   Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

EZH2↓, 1,   miR-21↓, 1,   miR-27a-3p↓, 1,   other↝, 2,   tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 1,  

Autophagy & Lysosomes ⓘ

LC3II↓, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   DNMT1↓, 1,   DNMTs↓, 1,   p16↑, 1,   P53↑, 1,   PCNA↓, 1,   TP53↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   P21↑, 1,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 5,   EMT↓, 2,   p‑ERK↓, 1,   GSK‐3β↓, 1,   HDAC↓, 1,   Nanog↓, 2,   NOTCH1↓, 1,   OCT4↓, 1,   PTEN↑, 1,   SOX2↓, 1,   STAT3↓, 3,   TOP1↓, 1,   TOP2↓, 1,   TumCG↓, 3,  

Migration ⓘ

AP-1↓, 1,   CXCL12↓, 1,   LAMs↓, 1,   MMP2↓, 1,   MMP9↓, 1,   MMPs↓, 1,   TGF-β↓, 1,   TumCP↓, 2,   TumMeta↓, 1,   TumMeta↑, 1,   α-SMA↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 3,   EGFR↓, 1,   EPR↑, 1,   Hif1a↓, 1,   NO↓, 1,   VEGF↓, 3,   ZBTB10↑, 1,  

Barriers & Transport ⓘ

GLUT1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   CRP↓, 1,   HCAR1↓, 1,   IL6↓, 1,   JAK2↓, 1,   NF-kB↓, 5,  

Cellular Microenvironment ⓘ

pH↑, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,   CYP19↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 10,   BioAv↑, 12,   ChemoSen↑, 4,   CYP17A1↓, 1,   Dose↑, 2,   Dose↝, 1,   Dose∅, 1,   eff↓, 1,   eff↑, 5,   Half-Life↓, 1,   Half-Life↝, 1,   Half-Life∅, 1,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

AR↓, 1,   CRP↓, 1,   EGFR↓, 1,   EZH2↓, 1,   IL6↓, 1,   TP53↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   chemoP↑, 1,   neuroP↑, 1,   toxicity↓, 1,  
Total Targets: 129

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 9,   GSH↑, 2,   HO-1↑, 2,   HO-2↓, 1,   lipid-P↓, 2,   MDA↓, 1,   Nrf1↑, 1,   NRF2↑, 1,   RNS↓, 1,   ROS↓, 7,   SOD↑, 2,  

Metal & Cofactor Biology ⓘ

Ferritin↑, 1,   IronCh↑, 3,  

Core Metabolism/Glycolysis ⓘ

LDL↓, 1,  

Cell Death ⓘ

Akt↑, 1,   Bcl-2↑, 1,   iNOS↓, 2,  

Transcription & Epigenetics ⓘ

Ach↑, 1,   HATs↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

HDAC↑, 1,   PI3K↑, 1,  

Migration ⓘ

AP-1↓, 2,   TGF-β↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↑, 1,  

Barriers & Transport ⓘ

BBB↑, 4,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   IL1↓, 1,   IL12↓, 1,   IL1β↓, 2,   IL2↓, 1,   IL6↓, 2,   IL8↓, 1,   Inflam↓, 7,   Inflam↑, 1,   NF-kB↓, 4,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,   ChAT↑, 1,   tau↓, 2,  

Protein Aggregation ⓘ

Aβ↓, 3,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 7,   BioAv↑, 10,   BioAv↝, 3,   Dose↝, 2,   eff↑, 4,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

Ferritin↑, 1,   GutMicro↑, 1,   IL6↓, 2,  

Functional Outcomes ⓘ

cognitive↑, 6,   cognitive↝, 1,   cognitive∅, 1,   memory↑, 4,   neuroP↑, 3,   toxicity↓, 1,   toxicity∅, 1,  
Total Targets: 56

Scientific Paper Hit Count for: BioAv, bioavailability
29 Curcumin
2 Piperine
1 Capsaicin
1 urea
1 Silver-NanoParticles
1 Silymarin (Milk Thistle) silibinin
1 EGCG (Epigallocatechin Gallate)
1 salinomycin
1 Selenium NanoParticles
1 Chemotherapy
1 Tomatine
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:65  Target#:792  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page